Christopher C. Thompson

Christopher C. Thompson

Auto-generated profile, based on publicly available information

Christopher C. Thompson

Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
BDBarham K. Abu Dayyeh
Barham K. Abu Dayyeh
DLDavid B. Lautz
David B. Lautz
CTChristopher C. Thompson
Christopher C. Thompson

6 February 2019 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
PGPhillip S. Ge
Phillip S. Ge
JYJoyce Y. Young
Joyce Y. Young
WDWilliam Dong
William Dong
CTChristopher C. Thompson
Christopher C. Thompson

20 October 2018 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
DCDaniel Castaneda
Daniel Castaneda
VPVioleta B. Popov
Violeta B. Popov
PWPraneet Wander
Praneet Wander
CTChristopher C. Thompson
Christopher C. Thompson

1 March 2017 in American Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
CTChristopher C Thompson
Christopher C Thompson
BDBarham K Abu Dayyeh
Barham K Abu Dayyeh
RKRobert Kushner
Robert Kushner
SSShelby Sullivan
Shelby Sullivan
ASAlan B Schorr
Alan B Schorr
LALouis J Aronne
Louis J Aronne
The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of an endoscopically placed percutaneous gastrostomy tube and an external device to facilitate drainage of about 30% of the calories consumed in a meal, in conjunction with lifestyle (diet and exercise) counseling. In this 52-week clinical trial, 207 participants with a body-mass index (BMI) of 35.0–55.0 kg/m2 were randomly assigned in a 2:1 ratio to treatment with AspireAssist plus Lifestyle Counseling (n=137; mean BMI was 42.2±5.1 kg/m2) or Lifestyle Counseling alone (n=70; mean BMI was 40.9±3.9 kg/m2). The co-primary end points were mean percent excess weight loss and the proportion of participants who achieved at least a 25% excess weight loss. At 52 weeks, participants in the AspireAssist group, on a modified intent-to-treat basis, had lost a mean (±s.d.) of 31.5±26.7% of their excess body weight (12.1±9.6% total body weight), whereas those in the Lifestyle Counseling group had lost a mean of 9.8±15.5% of their excess body weight (3.5±6.0% total body weight) (P<0.001). A total of 58.6% of participants in the AspireAssist group and 15.3% of participants in the Lifestyle Counseling group lost at least 25% of their excess body weight (P<0.001). The most frequently reported adverse events were abdominal pain and discomfort in the perioperative period and peristomal granulation tissue and peristomal irritation in the postoperative period. Serious adverse events were reported in 3.6% of participants in the AspireAssist group. The AspireAssist System was associated with greater weight loss than Lifestyle Counseling alone.

5 October 2006 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
CTC. C. Thompson
C. C. Thompson
JSJ. Slattery
J. Slattery
MBM. E. Bundga
M. E. Bundga
DLD. B. Lautz
D. B. Lautz

1 July 2013 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
CTChristopher C. Thompson
Christopher C. Thompson
BCBipan Chand
Bipan Chand
YCYang K. Chen
Yang K. Chen
DDDaniel C. DeMarco
Daniel C. DeMarco
LMLarry Miller
Larry Miller
MRMitchell S. Roslin
Mitchell S. Roslin